{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wijngaarden JE"],"funding":["Boehringer Ingelheim"],"pagination":["719-729"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11732896"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["52(2)"],"pubmed_abstract":["<h4>Introduction</h4>The novel positron emission tomography (PET) imaging tracer, [<sup>18</sup>F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [<sup>18</sup>F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.<h4>Methods</h4>Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input f"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Pharmacokinetic analysis and simplified uptake measures for tumour lesion [&lt;sup&gt;18&lt;/sup&gt;F]F-AraG PET imaging in patients with non-small cell lung cancer."],"pmcid":["PMC11732896"],"funding_grant_id":["Boehringer Ingelheim"],"pubmed_authors":["Levi J","Wijngaarden JE","Windhorst AD","Oordt CWMHV","Oprea-Lager DE","Slebe M","Dickhoff C","Thiele A","Schuit RC","Boellaard R","Yaqub M","Bahce I","Pouw JEE"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic analysis and simplified uptake measures for tumour lesion [&lt;sup&gt;18&lt;/sup&gt;F]F-AraG PET imaging in patients with non-small cell lung cancer.","description":"<h4>Introduction</h4>The novel positron emission tomography (PET) imaging tracer, [<sup>18</sup>F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [<sup>18</sup>F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.<h4>Methods</h4>Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input f","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-01T20:07:47.366Z","creation":"2025-04-06T01:16:14.398Z"},"accession":"S-EPMC11732896","cross_references":{"pubmed":["39377810"],"doi":["10.1007/s00259-024-06931-3"]}}